The site will be automated and remain a hub for sterile dosage forms and the commercial production of complex, personalised cell therapies, Novartis said in a statement on Tuesday. The company plans to invest $26 million (CHF21 million) to make this happen.

Novartis has started a consultation process, and affected staff will be covered by a social plan extended until 2028. The company says it will offer measures such as early retirement.

At the same time, Novartis plans to invest $80 million in its Schweizerhalle site, creating around 80 new full-time jobs by the end of 2028. The investment will support the development of siRNA, a key part of the group's strategy for tackling cardiovascular, kidney and metabolic diseases.

Translated from French with DeepL/sp

We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.

Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.

If you have any questions about how we work, write to us at ....

In compliance with the JTI standards

More: SWI swissinfo certified by the Journalism Trust Initiati

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at ....